Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys

  • Yong-Fu Xiao1Email author,

    Affiliated with

    • Bingdi Wang1,

      Affiliated with

      • Xiaoli Wang1,

        Affiliated with

        • Fenglai Du1,

          Affiliated with

          • Michael Benzinou1 and

            Affiliated with

            • Yi-Xin Jim Wang1

              Affiliated with

              BMC Anesthesiology201313:33

              DOI: 10.1186/1471-2253-13-33

              Received: 2 May 2013

              Accepted: 15 October 2013

              Published: 20 October 2013



              The α2-adrenoceptor agonist xylazine as an anesthetic has been widely used either alone or in combination with other anesthetics, such as ketamine, in veterinary clinic and research. In the last decade xylazine has been used in drug abusers in certain geographic area. This study investigated the effects of xylazine on blood glucose level and insulin secretion in normoglycemic and insulin-dependent diabetic monkeys.


              Both adult cynomolgus (n = 10) and rhesus (n = 8) monkeys with either sex were used in the study. Xylazine (1–2 mg/kg) was administrated intramuscularly. Blood glucose, insulin, glucagon and glucagon-like peptide 1 in overnight-fasted monkeys were measured immediately before and after xylazine administration. The hyperinsulinemic-euglycemic clamp method was used in the study for assessing the potential mechanism of xylazine-induced hyperglycemia.


              Xylazine administration increased the blood glucose levels from 58 ± 3 to 108 ± 12 mg/dL in normoglycemic (n = 5, p < 0.01) and from 158 ± 9 to 221 ± 13 mg/dL in insulin-dependent diabetic (n = 5, p < 0.01) monkeys and was not accompanied by any significant changes in blood insulin, glucagon, and glucagon-like peptide-1. Xylazine-induced hyperglycemia occurred within 10 min and reached the peak at 35 min after injection. Xylazine-induced hyperglycemia declined slowly in diabetic animals. The α2-adrenoceptor antagonist yohimbine was administrated to bring down the elevated glucose level to the pre-xylazine one in 4 out of 5 diabetic animals. To assess the potential mechanism, the hyperinsulinemic-euglycemic clamp was used to maintain a nearly saturated and constant insulin level for minimizing endogenous insulin glucoregulation. Xylazine administration decreased glucose infusion rate, from 14.3 ± 1.4 to 8.3 ± 0.8 mg/min/kg (n = 6, p < 0.01) in normoglycemic rhesus monkeys, which indicates that the glucose metabolic rate (M rate) was decreased by xylazine. In addition, after clamping blood glucose level in a range of 55 to 75 mg/dL for 40 min with constant glucose infusion, xylazine administration still increased blood glucose concentration.


              We conclude that xylazine administration induces hyperglycemia in normoglycemic and insulin-dependent diabetic monkeys potentially via stimulation of α2-adrenoceptors and then reducing tissue sensitivity to insulin and glucose uptake.


              Xylazine Hyperglycemia Monkey Insulin Glucose


              Xylazine is an α2-adrenoceptor agonist and shares the similar pharmacological properties with clonidine [14]. It has been widely used as a drug for sedation and analgesia in veterinary clinic and non-human mammal research for several decades [5, 6]. It can relieve pain and relax skeletal muscle. Xylazine is often co-administrated with ketamine to provide reliable anesthesia effects [7, 8]. The sedative and muscle-relaxing properties of xylazine can be beneficial in reducing ketamine-induced side effects, such as tremor and muscle rigidity. It also can reduce animal gastric and intestinal motility during gastrointestinal surgery or endoscopy. Its analgesic action is less than 30 min, but its sedative effect can last 2 hrs. Xylazine has adverse effects (e.g., cardiac conduction disturbances, bradycardia, and myocardial depression) similar to other α2 agonists. These adverse effects can be attenuated, blocked or reversed by adrenergic α2-receptor antagonists such as yohimbine [9, 10].

              Maintaining blood glucose homeostasis involves complex neurohumoral regulation. Stress can increase blood glucose by changing several hormones including insulin, glucagon, GLP-1, and catecholamines [11, 12]. Administration of the potent α2 agonist xylazine can result in a neurohumoral imbalance which affects blood glucose. In fact, several studies demonstrate that administration of xylazine increases blood glucose in various animal species, including dogs, cats, rats, and mice [1216].

              Currently, xylazine is not authorized for human use. However, early studies showed that xylazine induced sedation, muscle relaxation, and analgesia in healthy volunteers [17, 18]. All volunteers in those studies exhibited a significant reduction of blood pressure and heart rate. Interestingly, xylazine effectively lowered blood pressure and heart rate in some hypertensive patients [18, 19]. This veterinary anesthetic compound has been used as a new recreational drug among drug abusers in certain geographic areas [2024]. Chronic use of this substance induces physical dependence and open skin ulcers or abscesses [25]. More severe intoxication has been reported in xylazine users [19] and post-mortem examinations have attributed the death to xylazine (26–29). Medical examination in some drug-related deaths detected xylazine concurrently [2629].

              Previous studies show that xylazine increases blood glucose in both small and large animals [1214]. However, the effects of this drug on blood glucose homeostasis in non-human primates (NHPs) are unclear. The present study investigates the effects of xylazine on blood glucose in fasted, ketamine-anesthetized monkeys with or without diabetes. We also assessed xylazine’s effects on the secretion of insulin, glucagon, and glucagon-like peptide 1 (GLP-1). Understanding xylazine pharmacology and adverse effects in NHPs can provide useful information regarding its use in veterinary clinics and animal research as well as for proper therapy of abusers intoxicated with this α2-adrenoceptor agonist.


              Animal care and procedures

              Experiments were carried out in cynomolgus (Table 1) and rhesus monkeys of either sex. These monkeys were individually housed and maintained in our animal facility in accordance with guidelines approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Animals had continuous access to water ad libitum and controlled access to food. Room temperature was maintained at ∼ 21°C. The animals were maintained on a 12 hr light/dark cycle with lights off from 6 PM to 6 AM. The monkeys were maintained with a complete nutritionally balanced diet (Shanghai Shilin Biotechnology, Inc., Shanghai, China) and enriched with seasonal fruits and vegetables. The experimental protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Crown Bioscience, Inc.
              Table 1

              Characteristics of the diabetic and normoglycemic cynomolgus monkeys used



              Age (year)

              Body weight (kg)

              Fasting glucose (mg/dL)

              Fasting insulin (μIU/ml)



              6.8 ± 0.3

              6.7 ± 0.7

              47.9 ± 5.4

              23.9 ± 3.9



              18.3 ± 0.8***

              6.0 ± 0.7

              183.6 ± 29.8***

              12.1 ± 0.7***

              Values are expressed as the mean ± SEM. Normal, normoglycemic monkeys; Diabetic, insulin-dependent diabetic monkeys; ***, p < 0.001; vs. normal.

              On the experimental day each monkey was fasted overnight and received ketamine (10 mg/kg, Fujian Gutian Pharmaceutical Co. Ltd., Fujian, China) intramuscular administration. Sedation was maintained with additional ketamine (5 mg/kg) injection as needed. Xylazine and yohimbine (Sigma-Aldrich Co., St. Louis, MO, USA) were given intramuscularly for testing their effects on blood glucose. Body temperature was maintained during each experiment at ~37°C by a thermostatically controlled warm water–circulating pad placed beneath the body. Food and water were provided again after experimental animals were returned to their cages and fully recovered from anesthesia.

              Blood collection and handling

              Whole blood samples (1–2 ml/per time) at various time points after anesthesia or compound treatment were collected from a plastic needle inserted into an arm vein. Samples were collected into an EDTA-washed (0.5 M EDTA, pH 8.0, Gibco, Invitrogen Corporation, Grand Island, NY, USA) 2.5-mL disposable syringe and transferred immediately into a 5-ml Monoject™ blood collection tube containing 7.5 mg EDTA (Sherwood Medical, St. Louis, MO, USA). The collection tube also contained aprotinin (Sigma-Aldrich Co., St. Louis, MO, USA) for reduction of protein degradation and DPP IV inhibitor (EMD Millipore Corporation, Billerica, MA, USA) for prevention of GLP-1 degradation. Blood samples were centrifuged within 30 min at 4°C, 3000 g for 10 min and then the plasma was separated following standard protocols established in our laboratory. The plasma samples were kept in a freezer at -80°C prior to analysis of glucose, insulin, glucagon, and GLP-1 concentrations.

              Intravenous glucose tolerance test (ivGTT)

              To evaluate the β-cell function ivGTT was performed in the diabetic and normoglycemic monkeys according to the method reported previously [30, 31]. The animals were fasted for 16 hrs and anesthetized with an initial dose of ketamine at 15 mg/kg (i.m.) with additional doses during the procedure if needed. The cephalic and/or saphenous veins were cannulated separately for glucose infusion and blood collection. Glucose (0.25 g/kg = 0.5 ml/kg of 50% dextrose) was intravenously infused during 30 sec and the system was flushed with 5 ml heparinized saline to remove residual glucose. Blood was collected immediately before and at 3, 5, 7, 10, 15, 20, 30 min after glucose infusion. Blood samples were immediately transferred to heparinized and chilled tubes on ice. Plasma was then separated and stored at -80°C for subsequent assays.

              Hyperinsulinemic-euglycemic clamp

              Hyperinsulinemic-euglycemic clamp analysis was performed in 16-hr-fasted monkeys under ketamine-anesthesia. Cannulation of the cephalic and/or saphenous veins was conducted for insulin and glucose infusion, and blood drawing for glucose measurement. Insulin (biosynthetic human insulin, Novo Nordisk, Denmark) was diluted to 300 mU/ml by isotonic saline to which 2 ml of the subject’s blood per 50 ml was added in order to avoid adhesion of insulin to the syringe plastic surface. Insulin infusion at various rates was given during the 1st 10 min to quickly adjust blood glucose near a targeted level. The infusion rate for the hyperinsulinemic-euglycemic clamp was then maintained at 40 mU/m2 Surface Area*min as reported previously [32].

              A variable amount of 20% D-glucose was intravenously infused to maintain blood glucose. Blood samples were taken every 5 min and glucose was measured by a glucose analyzer (Accu-Chek Active, Roche Diagnostics, Indianapolis, IN, USA) to allow adjustment of the glucose infusion rate accordingly. In the 1st set of experiments, when blood glucose was adjusted and balanced for approximately 120 to 150 min and then for a 40-min stable period of glucose levels clamped in a range of 55 to 75 mg/dL under constant infusion of glucose, xylazine was injected intramuscularly. Blood glucose concentration was monitored for another 30 to 40 min after xylazine injection. In the 2nd set of experiments, xylazine was injected after blood glucose level was adjusted for 95 to 135 min and then maintained in the range of 55 to 75 mg/dL for 40 min. The glucose infusion rate was adjusted after xylazine treatment to clamp blood glucose in the range of 55–75 mg/dL. The difference of the glucose metabolic rates (M rate) was calculated from the glucose infusion rates before and after xylazine treatment.

              Data analysis

              Data were expressed as mean ± SEM. Statistical significance for multiple observation parameters in the same group was determined by One-way Analysis of Variance (ANOVA). If statistical significance of differences was detected, then Tukey’s Multiple Comparison Test (GraphPad Software, Inc., La Jolla, CA, USA) was also conducted. The comparison between diabetic and normoglycemic groups was tested by the un-paired t-test. Statistical significance was considered if p value was <0.05.


              Selection of diabetic monkeys

              As the effects of xylazine on blood glucose had not been studied in NHPs previously, we selected diabetic and normoglycemic monkeys for this study. Based on blood glucose (<90 mg/dL) and other biochemistry tests, five healthy young cynomolgus monkeys were selected for the normoglycemic group (Table 1). The other five cynomolgus monkeys were selected from spontaneously naturally developed and already insulin-treated diabetic animals with blood glucose >150 mg/dL. Compared with controls, the diabetic animals were significantly older (Table 1). They received insulin treatment daily because of their high blood glucose, low insulin, and losing body weight if not insulin-treated.

              The selected animals were characterized by intravenous glucose tolerance test (ivGTT) and insulin secretion assay. Figure 1A shows that blood glucose and insulin were significantly increased immediately after glucose challenge in normoglycemic monkeys who had normal β-cell function. The significant increase in blood glucose lasted 20 min and 15 min in insulin and then returned to the control levels within 30 min. However, in the insulin-dependent diabetic monkeys only blood glucose was significantly increased without significant alteration of insulin (Figure 1B). The glucose AUC (area under the curve) was significantly higher in the diabetic monkeys than in the normoglycemic ones (Figure 1C, p < 0.01). In contrast, the insulin AUC was significantly lower in the diabetic monkeys than in the normoglycemic ones (Figure 1D, p < 0.05). These results indicate that pancreatic function was normal in the normoglycemic monkeys and was significantly impaired in the diabetic ones. To look at the differences between the strains and their xylazine responses, eight normal rhesus monkeys were also used for xylazine test during glucose clamp.
              Figure 1

              Intravenous glucose tolerance test (ivGTT) in normoglycemic and insulin-dependent diabetic cynomolgus monkeys (Table 1 ). Plasma glucose and insulin levels were measured at the scheduled time points in normoglycemic (panel A, n = 5) and insulin-dependent diabetic (panel B, n = 5) monkeys. Panel C shows the glucose AUCs of the ivGTTs for the nomorglycemic (blank bar) and diabetic (strip bar) monkeys. Panel D shows the insulin AUCs of the ivGTTs for the normoglycemic (blank bar) and diabetic (strip bar) monkeys. *, p < 0.05; **, p < 0.01, ***, p < 0.001; vs. the level at time zero or vs. the normoglycemic group.

              Xylazine-induced hyperglycemia in diabetic and normoglycemic monkeys

              After verification of the pancreatic functions in the selected diabetic and normoglycemic monkeys, the effects of xylazine on blood glucose were investigated. Blood glucose was measured immediately before and at various time points over the 2 hr observation (Figure 2A). Intramuscular injection of xylazine (1–2 mg/kg) significantly increased blood glucose in a time-dependent manner in the normoglycemic monkeys (Figure 2A, open circle). An initial rise of blood glucose was observed at 5 to 10 min after xylazine injection. The increase reached the peak of 108 ± 12 mg/dL from the baseline of 58 ± 3 mg/dL (p < 0.01) at approximately 35 min following xylazine administration. Hyperglycemia began to decline approximately 45 min after xylazine injection. Blood glucose in all of the normoglycemic monkeys gradually returned to the pre-xylazine levels within 2 hrs (Figure 2A, open cycle).
              Figure 2

              Hyperglycemic effects of xylazine in fasted, ketamine-anesthetized cynomolgus monkeys. Panel A shows the time-dependent effects of xylazine in normoglycemic (open circle, n = 5) and insulin-dependent diabetic (solid circle, n = 5) monkeys. The dotted lines show the pre-xylazine glucose levels in normoglycemic and insulin-dependent diabetic monkeys. The time-dependent effects of xylazine on plasma insulin and glucagon are shown in panel B and C, respectively. , the time point that xylazine (1–2 mg/kg) was injected intramuscularly. **, p < 0.01; vs. the baseline level at time zero.

              Xylazine-induced hyperglycemia was also observed in the diabetic monkeys (n = 5). Xylazine administration (1–2 mg/kg) increased blood glucose from the baseline of 158 ± 9 mg/dL to 221 ± 13 mg/dL at approximately 35 min following the injection (p < 0.05, Figure 2A, filled cycle). The initial rise and time to the peak after xylazine administration were very similar to those observed in the normoglycemic monkeys. However, the initial decline of blood glucose was delayed to approximately 60 min after xylazine administration. The decline toward the pre-xylazine level was much slower in the diabetic monkeys than in the normoglycemic ones (Figure 2A, dot line). Blood glucose remained high 2 hrs after xylazine administration (Figure 2A, filled circle). Only one out of 5 diabetic monkeys gradually returned to the pre-xylazine glucose level at 2 hr after xylazine administration. The other diabetic animals retained their elevated glucose levels 2 hrs after xylazine injection and the α2-adrenoceptor antagonist yohimbine (1–4 mg/kg) was injected to restore blood glucose toward the pre-xylazine levels for safety reason.

              Effects of xylazine on glucoregulatory hormones

              To assess the possible mechanism of xylazine-induced hyperglycemia, plasma insulin, glucagon, and GLP-1 were measured in both diabetic and normoglycemic monkeys. As shown in Figure 2B (open cycles), the baseline level of plasma insulin in the normoglycemic monkeys was 15.1 ± 8.3 μIU/ml (n = 3). Xylazine administration (1–2 mg/kg) did not cause statistically significant alterations of plasma insulin in the non-diabetic monkeys (p > 0.05). Compared to the non-diabetes, the plasma insulin level was relatively lower in the diabetic monkeys (11.2 ± 4.8 μIU/ml, n = 5) and remained unchanged during 90-min observation after xylazine administration (Figure 2B, solid cycle).

              The mean plasma glucagon levels were 0.47 ± 0.10 nM (n = 3) for the normoglycemic and 0.51 ± 0.02 nM (n = 5) for the insulin-dependent diabetic monkeys. Xylazine administration (1–2 mg/kg) did not alter the levels of plasma glucagon in either group (Figure 2C, p > 0.05). In addition, xylazine had no statistically significant effects on plasma GLP-1 level in both diabetic and normoglycemic monkeys. The baseline plasma GLP-1 level was 1.32 ± 0.14 pM (n = 3) for the normoglycemic monkeys and 2.52 ± 0.95 pM (n = 5) for the diabetic ones. The plasma GLP-1 level was 1.50 ± 0.64 pM for the normoglycemic monkeys and 2.43 ± 1.39 pM for the diabetic animals at 30 min after xylazine injection.

              Effects of xylazine on blood glucose during hyperinsulinemic-euglycemic clamp

              To exclude or minimize the influence of endogenous insulin on xylazine-induced hyperglycemia and also to see the effects of xylazine on blood glucose in another monkey strain (rhesus), the hyperinsulinemic-euglycemic clamp was performed in normoglycemic rhesus monkeys of either sex (n = 8). Their mean age was 10.7 ± 1.1 years with the body weight of 7.7 ± 0.8 kg. Compared with the normoglycemic cynomolgus monkeys (Table 1, 47.9 ± 5.4 mg/dL), their blood glucose was significantly higher (86 ± 4.6 mg/dL) probably due to their older ages. They were intravenously infused with a constant dose of insulin following an initial bolus infusion in the 1st 10 min (Figure 3, open square). Glucose was simultaneously infused with rates adjusted until blood glucose was maintained in a range of 55 to 75 mg/dL under a constant infusion rate (Figure 3, open triangle). Prior to xylazine injection, a 40 min period (from 150–190 min after the initiation of the clamp, Figure 3) of stable blood glucose ranging from 55 to 75 mg/dL was reached (Figure 3). Administration of xylazine (2 mg/kg) significantly increased blood glucose level, from 55 mg/dL (left panel) and 64 mg/dL (right panel) for pre-xylazine to the peak of 83 mg/dL (left panel) and 99 mg/dL (right panel), respectively, despite the glucose infusion rate being unchanged. These results indicate that xylazine still produced hyperglycemia in the presence of clamp-maintained hyperinsulinemia which maximally inhibited endogenous negligible insulin secretion.
              Figure 3

              Effects of xylazine on blood glucose concentrations in two fasted normoglycemic rhesus monkeys during the hyperinsulinemic-euglycemic clamp. Insulin was given with an initial bolus infusion to reduce blood glucose close to a targeted level followed by a constant infusion rate of 40 mU/m2 Surface Area*min (open squares) for maintaining hyperinsulinemia. Glucose was infused simultaneously with adjustable rates to clamp blood glucose in the euglycemic range of 55 – 75 mg/dL (open triangles). Xylazine (2 mg/kg) was injected intramuscularly after 40-min euglycemia stabilization to observe its effects on blood glucose when glucose was infused at a constant rate.

              To further investigate the role of insulin in xylazine-induced hyperglycemia, another set of experiments was conducted in normoglycemic monkeys who were clamped for maintaining hyperinsulinemia to minimize endogenous insulin glucoregulation. When blood glucose in these animals reached 40-min stabilization in a range of 55 to 75 mg/dL under constant glucose infusion, xylazine (2 mg/kg) was intramuscularly administrated. In order to hold the blood glucose level in the constant range of 55 to 75 mg/dL by the negative feedback principle, the glucose infusion rate was significantly reduced, from 14.3 ± 1.4 mg/min/kg for pre-xylazine (Figure 4, open bar) to 8.3 ± 0.8 mg/min/kg for post-xylazine (Figure 4, striped bar, n = 6, p < 0.01). Under these steady-state conditions of normoglycemia, the glucose infusion rate equals glucose uptake of the body and is therefore a measure of tissue sensitivity to exogenous insulin. These results support our hypothesis that xylazine-induced hyperglycemia most likely resulted from a reduction of tissue sensitivity to insulin, because blood insulin was stably maintained at a high level by a constant infusion.
              Figure 4

              Effects of xylazine on the glucose metabolic rate in fasted normoglycemic rhesus monkeys. Hyperinsulinemia was maintained by insulin infusion at a constant rate of 40 mU/m2 Surface Area*min. Glucose was infused simultaneously to adjust and balance blood glucose for a period of 95 ± 11 min and then to achieve euglycemia (55 – 75 mg/dL) stably for 40 min with a constant infusion rate. Xylazine (2 mg/kg) was then injected intramuscularly. To hold blood glucose concentration constantly in the pre-xylazine range (55 – 75 mg/dL), the glucose infusion rate was decreased during next 40 min after xylazine administration. The glucose infusion rates were calculated as the glucose metabolic rates (M rates) at the times before (Pre-xylazine) and after (Xylazine) xylazine administration. **, p < 0.01; vs. Pre-xylazine.


              The main finding of this study is that xylazine administration produced an acute hyperglycemia without significant changes in blood insulin, glucagon, and GLP-1 in both insulin-dependent diabetic and normoglycemic monkeys. As xylazine is widely used either alone or combined with other anesthetics, such as ketamine, in various animal research, its hyperglycemia can have an obvious impact on experimental results, especially in diabetic and metabolic research. Xylazine is commonly used as an anesthetic and analgesic in veterinary clinics [5, 6]. Also, due to increasing amongst drug abusers [2022], xylazine-induced hyperglycemia potentially becomes a clinically relevant issue, especially in diabetic subjects.

              Xylazine-induced hyperglycemia was reported previously in various species, including dogs [11], cattle [33, 34], and rats [12, 35]. However, these studies were performed in normoglycemic animals. These studies led to the hypothesis that the inhibition of insulin secretion plays a critical role in the hyperglycemia. The present study attempts to test this hypothesis in a series of 3 experiments. First, we used naturally developed diabetic monkeys who required insulin treatment because their insulin secretory function was greatly diminished. Our data clearly demonstrate that xylazine not only produced profound hyperglycemia in the normoglycemic monkeys, but also in the diabetic animals (Figure 2). Secondly, blood insulin, glucagon, and GLP-1 exhibited no significant changes during the xylazine-induced hyperglycemic period (Figure 2). Thirdly, xylazine still caused hyperglycemia (Figure 3) and decreased glucose uptake (M rate, Figure 4) during hyperinsulinemic-euglycemic clamp. These results are consistent with those reported in foals that insulin was not significantly changed during xylazine-produced hyperglycemia [36]. However, xylazine-induced hyperglycemia in rats, sheep, cattle, and dogs is associated with a reduction of insulin secretion [35, 3741], while a significant rise in plasma insulin levels occurs in horses [42]. These inconsistent results may be due to different animal species used. Our results suggest that xylazine-induced hyperglycemia results from the decrease of tissue sensitivity to insulin, which leads to the reduction of tissue glucose uptake and utilization.

              Xylazine is an analogue of the α2-adrenergic agonist clonidine. The effects of activation of α2-adrenoceptors on blood glucagon are inconsistent and whether the hyperglycemic effect of xylazine involves glucagon is not clear [37, 43]. Previous studies in rats showed that xylazine significantly increased blood glucagon, which was not affected by the α2-adrenergic antagonist yohimbine [1, 12, 35]. The unchanged glucagon level found in our present study is consistent with the results previously reported in dogs [11]. Glucagon thus seems not so critical for xylazine-induced hyperglycemia at least in NHPs in this study. Furthermore, blood GLP-1 was also not altered after xylazine administration in the present study. Therefore, it is possible that the cause of xylazine-induced hyperglycemia results from stimulation of α2-adrenoceptors and then modifying other stress hormones, such as ACTH and GH, which were not measured in our study. However, xylazine has been reported to increase the release of ACTH and GH in cattle and dogs [3, 39].

              It is unclear whether xylazine itself could increase hepatic glucose production (glycogenolysis and gluconeogenesis) and then cause hyperglycemia. However, as xylazine-induced hyperglycemia observed in the present study was conducted in fasted monkeys which had reduced glycogen stores [44], the contribution of glycogenolysis to the hyperglycemia was very unlikely, especially in fasted insulin-dependent diabetic monkeys. In addition, the level of blood glucagon (the stimulating hormone of glycogenolysis and gluconeogenesis) was not increased in the presence of xylazine (Figure 2C). Therefore, xylazine-induced hyperglycemia was unlikely via an increase in hepatic glucose production.

              Compared with the insulin-dependent diabetic monkeys, the decline of xylazine-induced hyperglycemia was faster and blood glucose returned to the pre-xylazine level within 90 min in normoglycemic monkeys (Figure 2A). In contrast, blood glucose remained elevated during the entire observation period of 120 min in the diabetic monkeys. The specific α2-adrenoceptor antagonist yohimbine had to be given in 4 out of 5 insulin dependent diabetic monkeys to decrease their blood glucose to the pre-xylazine level for animal safety reason. These results suggest that xylazine-induced hyperglycemia is mediated, at least partially, via stimulation of α2-adrenoceptors. Lattermann and colleagues reported that blood glucose concentrations were significantly increased in patients during and after lower abdominal surgery [45]. However, compared with control patients (saline), intraoperative glucose plasma concentrations were even higher in the patients who received clonidine (1 μg/kg) 30 min before induction of general anesthesia. The adverse effects of hyperglycemia can be reflected in animal models of myocardial infarction [46] and in patients after acute myocardial infarction [47], stroke [48], and cardiac surgery [49]. Therefore, great care should be taken to avoid using an agent which causes hyperglycemia and influences outcome.

              Due to the difficulty of obtaining traditional illicit drugs, consumption in drug abusers is turning towards less restricted compounds. Xylazine, the veterinary sedative anesthetic, was confirmed as the anesthetic substance used in Puerto Rico by testing exchanged needles in 29 sites in 11 municipalities [22]. Xylazine used as adulterants in heroin was also found in drug related deaths in Philadelphia, Pennsylvania [20, 50]. An 18-year-old man after inhaling xylazine showed chills and dizziness followed by sweating, gait instability, palpitations and syncope with bradycardia and hypotension. More cases of toxicity caused by xylazine consumption have been documented in humans, occasionally resulting in death [18, 20, 28]. Xylazine users could become apneic and require intubation and mechanical ventilation. Two critical issues about chronic use of xylazine are the physical dependence and the noticeable open skin ulcers [6]. These ulcers are referred to as abscesses and are a serious health concern. The pain caused by the ulcers promotes further injections of xylazine because of its sedative/anesthetic effects. These open skin ulcers emit a strong odor, ooze, and in severe cases limit the mobility of the extremities with a possibility of amputation [25]. In xylazine abusers (generally male with a mean age of 30 years) 35% have skin lesions, which leads to more social exclusion. It is unclear whether the skin ulcers result from the hyperglycemic effect of xylazine in abusers, because extremity infection in diabetic patients is common and severe, sometimes difficult to cure [22]. More experiments are thus required to elucidate how xylazine induces hyperglycemia at the cellular and molecular levels, which may have clinical relevance.


              In conclusion, the anesthetic xylazine can cause acute hyperglycemia with no significant alterations of blood insulin, glucagon, and GLP-1 in normoglycemic and insulin-dependent diabetic non-human primates. Such hyperglycemia is most likely via xylazine stimulation of α2-adrenoceptors and subsequent reduction of tissue sensitivity to insulin and glucose uptake.


              Authors’ Affiliations

              Cardiovascular and Metabolic Disease Research, Crown Bioscience Inc, Science and Technology Park


              1. Peng M, Li Y, Luo Z, Liu C, Laties AM, Wen R: Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Muller cells in vivo. Invest Ophthalmol Vis Sci 1998,39(9):1721–1726.PubMed
              2. Gallanosa AG, Spyker DA, Shipe JR, Morris DL: Human xylazine overdose: a comparative review with clonidine, phenothiazines, and tricyclic antidepressants. Clin Toxicol 1981,18(6):663–678.PubMedView Article
              3. Hampshire J, Altszuler N: Clonidine or xylazine as provocative tests for growth hormone secretion in the dog. Am J Vet Res 1981,42(6):1073–1076.PubMed
              4. Tita B, Leone MG, Casini ML, Corubolo C, Bordi F, Guidolin D, Fumagalli E, Romanelli L, Mattioli F, Feher J, et al.: Corneal toxicity of xylazine and clonidine, in combination with ketamine, in the rat. Ophthalmic Res 2001,33(6):345–352.PubMedView Article
              5. Banknieder AR, Phillips JM, Jackson KT, Vinal SI Jr: Comparison of ketmine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulatta). Lab Anim Sci 1978,28(6):742–745.PubMed
              6. Wright M: Pharmacologic effects of ketamine and its use in veterinary medicine. J Am Vet Med Assoc 1982,180(12):1462–1471.PubMed
              7. Green CJ, Knight J, Precious S, Simpkin S: Ketamine alone and combined with diazepam or xylazine in laboratory animals: a 10 year experience. Lab Anim 1981,15(2):163–170.PubMedView Article
              8. Naccarato EF, Hunter WS: Anaesthetic effects of various ratios of ketamine and xylazine in rhesus monkeys (Macacca mulatta). Lab Anim 1979,13(4):317–319.PubMedView Article
              9. El Motal SM A, Sharp GW: Inhibition of glucose-induced insulin release by xylazine. Endocrinology 1985,116(6):2337–2340.View Article
              10. Stewart MC, English AW: The reversal of xylazine/ketamine immobilisation of fallow deer with yohimbine. Aust Vet J 1990,67(9):315–317.PubMedView Article
              11. Ambrisko TD, Hikasa Y: Neurohormonal and metabolic effects of medetomidine compared with xylazine in beagle dogs. Can J Vet Res 2002,66(1):42–49.PubMed
              12. Saha JK, Xia J, Engle SK, Chen YF, Glaesner W, Jakubowski JA: A model of controlled acute hyperglycemia in rats: effects of insulin and glucagon-like peptide-1 analog. J Pharmacol Exp Ther 2006,316(3):1159–1164.PubMedView Article
              13. Martin IK, McDonald IR: Adrenocortical functions in a macropodid marsupial thylogale billardierii. J Endocrinol 1986,110(3):471–480.PubMedView Article
              14. Ambrisko TD, Hikasa Y, Sato K: Influence of medetomidine on stress-related neurohormonal and metabolic effects caused by butorphanol, fentanyl, and ketamine administration in dogs. Am J Vet Res 2005,66(3):406–412.PubMedView Article
              15. Brown ET, Umino Y, Loi T, Solessio E, Barlow R: Anesthesia can cause sustained hyperglycemia in C57/BL6J mice. Vis Neurosci 2005,22(5):615–618.PubMedView Article
              16. Kanda T, Hikasa Y: Neurohormonal and metabolic effects of medetomidine compared with xylazine in healthy cats. Can J Vet Res 2008,72(3):278–286.PubMed
              17. Fyffe JJ: Effects of xylazine on humans: a review. Aust Vet J 1994,71(9):294–295.PubMedView Article
              18. Elejalde JI, Louis CJ, Elcuaz R, Pinillos MA: Drug abuse with inhalated xylazine. Eur J Emerg Med 2003,10(3):252–253.PubMedView Article
              19. Capraro AJ, Wiley JF 2nd, Tucker JR: Severe intoxication from xylazine inhalation. Pediatr Emerg Care 2001,17(6):447–448.PubMedView Article
              20. Wong SC, Curtis JA, Wingert WE: Concurrent detection of heroin, fentanyl, and xylazine in seven drug-related deaths reported from the Philadelphia medical Examiner’s office. J Forensic Sci 2008,53(2):495–498.PubMedView Article
              21. Torruella RA: Xylazine (veterinary sedative) use in Puerto Rico. Subst Abuse Treat Prev Policy 2011, 6:7.PubMedView Article
              22. Rodriguez N, Vargas Vidot J, Panelli J, Colon H, Ritchie B, Yamamura Y: GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend 2008,96(3):290–293.PubMedView Article
              23. Reyes JC, Negron JL, Colon HM, Padilla AM, Millan MY, Matos TD, Robles RR: The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health 2012,89(3):519–526.PubMedView Article
              24. Lopez Briz E, Barreda Aznar A, Guevara Serrano J, Blasco M: Veterinary drugs: a new source of drug abuse? Med Clin (Barc) 1991,96(11):437.
              25. Room R: Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev 2005,24(2):143–155.PubMedView Article
              26. Liu CM, Chiu MJ, Fang CC, Chen WJ: Xylazine abuse: a rare cause of syncope. Clin Toxicol (Phila) 2007,45(3):309–311.View Article
              27. Poklis A, Mackell MA, Case ME: Xylazine in human tissue and fluids in a case of fatal drug abuse. J Anal Toxicol 1985,9(5):234–236.PubMedView Article
              28. Moore KA, Ripple MG, Sakinedzad S, Levine B, Fowler DR: Tissue distribution of xylazine in a suicide by hanging. J Anal Toxicol 2003,27(2):110–112.PubMedView Article
              29. Mittleman RE, Hearn WL, Hime GW: Xylazine toxicity–literature review and report of two cases. J Forensic Sci 1998,43(2):400–402.PubMed
              30. Hansen BC: Investigation and treatment of type 2 diabetes in nonhuman primates. Methods Mol Biol 2012, 933:177–185.PubMed
              31. Hansen BC, Bodkin NL: Standardization of IVGTT. Importance of method used to calculate glucose disappearance. Diabetes Care 1993,16(5):847.PubMed
              32. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979,237(3):E214-E223.PubMed
              33. Eichner RD, Prior RL, Kvasnicka WG: Xylazine-induced hyperglycemia in beef cattle. Am J Vet Res 1979,40(1):127–129.PubMed
              34. Brearley JC, Dobson H, Jones RS: Investigations into the effect of two sedatives on the stress response in cattle. J Vet Pharmacol Ther 1990,13(4):367–377.PubMedView Article
              35. Saha JK, Xia J, Grondin JM, Engle SK, Jakubowski JA: Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Exp Biol Med (Maywood) 2005,230(10):777–784.
              36. Robertson SA, Carter SW, Donovan M, Steele C: Effects of intravenous xylazine hydrochloride on blood glucose, plasma insulin and rectal temperature in neonatal foals. Equine Vet J 1990,22(1):43–47.PubMedView Article
              37. Goldfine ID, Arieff AI: Rapid inibition of basal and glucose-stimulated insulin release by xylazine. Endocrinology 1979,105(4):920–922.PubMedView Article
              38. Muggaberg J, Brockman RP: Effect of adrenergic drugs on glucose and plasma glucagon and insulin responses to xylazine in sheep. Res Vet Sci 1982,33(1):118–120.PubMed
              39. Kasuya E, Hodate K, Matsumoto M, Sakaguchi M, Hashizume T, Kanematsu S: The effects of xylazine on plasma concentrations of growth hormone, insulin-like growth factor-I, glucose and insulin in calves. Endocr J 1996,43(2):145–149.PubMedView Article
              40. Kasuya E, Hodate K, Matsumoto M, Sakaguchi M, Hashizume T, Kanematsu S: Effects of atipamezole, an alpha 2-adrenergic antagonist, and somatostatin on xylazine-induced growth hormone release in calves. Endocr J 1996,43(5):551–556.PubMedView Article
              41. Rizk A, Herdtweck S, Meyer H, Offinger J, Zaghloul A, Rehage J: Effects of xylazine hydrochloride on hormonal, metabolic, and cardiorespiratory stress responses to lateral recumbency and claw trimming in dairy cows. J Am Vet Med Assoc 2012,240(10):1223–1230.PubMedView Article
              42. Robertson SA, Steele CJ, Chen CL: Metabolic and hormonal changes associated with arthroscopic surgery in the horse. Equine Vet J 1990,22(5):313–316.PubMedView Article
              43. Brockman RP: Effect of xylazine on plasma glucose, glucagon and insulin concentrations in sheep. Res Vet Sci 1981,30(3):383–384.PubMed
              44. Geary N, Langhans W, Scharrer E: Metabolic concomitants of glucagon-induced suppression of feeding in the rat. Am J Physiol 1981,241(5):R330-R335.PubMed
              45. Lattermann R, Schricker T, Georgieff M, Schreiber M: Low dose clonidine premedication accentuates the hyperglycemic response to surgery. Can J Anaesth 2001,48(8):755–759.PubMedView Article
              46. Shiomi T, Tsutsui H, Ikeuchi M, Matsusaka H, Hayashidani S, Suematsu N, Wen J, Kubota T, Takeshita A: Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 2003,42(1):165–172.PubMedView Article
              47. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000,355(9206):773–778.PubMedView Article
              48. Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KG, Gray CS: Blood pressure response to glucose potassium insulin therapy in patients with acute stroke with mild to moderate hyperglycaemia. J Neurol Neurosurg Psychiatry 2001,70(3):401–404.PubMedView Article
              49. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 2001,345(19):1359–1367.PubMedView Article
              50. Hsu WH, Hummel SK: Xylazine-induced hyperglycemia in cattle: a possible involvement of alpha 2-adrenergic receptors regulating insulin release. Endocrinology 1981,109(3):825–829.PubMedView Article
              51. Pre-publication history

                1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2253/​13/​33/​prepub


              © Xiao et al.; licensee BioMed Central Ltd. 2013

              This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.